Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism (Q46111551)

19 December 2017

title

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism (English)

1 reference

19 December 2017

0 references

1 reference

4

1 reference

19 December 2017

Mikko Niemi

5

1 reference

19 December 2017

author name string

A Kalliokoski

1

1 reference

19 December 2017

J T Backman

2

1 reference

19 December 2017

K J Kurkinen

3

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

19 December 2017

volume

84

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

488-496

1 reference

19 December 2017

Insulinotropic meglitinide analogues

cites work

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Clinical pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 C1007G, by using transient expression systems of HeLa and HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Pharmacologic treatment of type 2 diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Cyclosporine markedly raises the plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

inferred from DOI database lookup

7 January 2021

based on heuristic

Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine

1 reference

https://api.crossref.org/works/10.1038/CLPT.2008.74

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2008.74

1 reference

19 December 2017

1 reference

19 December 2017